News Amgen Inc.

Equities

AMGN

US0311621009

Real-time Estimate Cboe BZX Other stock markets 01:10:10 2024-04-26 pm EDT			5-day change	1st Jan Change
269.8 ^USD	+0.17%		+0.36%	-6.29%

05:03pm	Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe	MT
03:38pm	Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amgen to Submit Thyroid Eye Disease Treatment Marketing Authorization Application in Europe	11:03am	MT
Amgen to Seek European OK of Thyroid Eye Disease Drug Tepezza	09:38am	DJ
AMGEN TO SUBMIT TEPROTUMUMAB MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY	09:01am	PR
Amgen : How Amgen’s Real-World Evidence Is Changing The Future of Patient Care in Psoriatic Disease	Apr. 24	PU
The Pleading Standard For Complex Technology? It's Complex.	Apr. 23	AQ
MDL Panel Grants Transfer Of Aflibercept BPCIA Case	Apr. 22	AQ
Wall Street: tech and SOXX in free fall this week	Apr. 22	CF
Wall Street: tech and SOXX in free fall this week	Apr. 19	CF
Amgen : First Cancer Diagnosis Led to a Dark Place—Aiding Another Helped Lift Him Out of It	Apr. 17	PU
AMGEN TO PRESENT TEZSPIRE PHASE 2A COPD DATA AT ATS 2024	Apr. 17	AQ
UBS Adjusts Amgen's Price Target to $284 From $314, Maintains Neutral Rating	Apr. 17	MT
Amgen Plans for Phase 3 Trial of Tezepelumab for Lung Disease	Apr. 16	MT
Navigating the Landscape of Precision Medicine in Gastric Cancer: FGFR2b Protein Overexpression as an Emerging Biomarker	Apr. 16	PU
TD Cowen Cuts Price Target on Amgen to $360 From $370, Buy Rating Kept	Apr. 15	MT
Goldman Sachs Adjusts Amgen Price Target to $359 From $361, Maintains Buy Rating	Apr. 15	MT
Neumora's early-stage schizophrenia drug study put on hold	Apr. 15	RE
BMO Lowers Price Target on Amgen to $336 From $343	Apr. 12	MT
Amgen : CEO Bob Bradway's 2023 Letter to Shareholders	Apr. 10	PU
Amgen : Chairman and CEO Letter and Amgen Inc. 2023 Annual Report	Apr. 10	PU
Morgan Stanley Raises 2024, 2025 EPS Estimates for Regeneron Pharmaceuticals, Amgen	Apr. 09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Amgen Inc.

Equities

AMGN

US0311621009

Summary

Filters